Letter | Published:

Regulation of osteoclast differentiation and function by the CaMK-CREB pathway

Abstract

Calcium (Ca2+) signaling is essential for a variety of cellular responses and higher biological functions. Ca2+/calmodulin-dependent kinases (CaMKs) and the phosphatase calcineurin activate distinct downstream pathways that are mediated by the transcription factors cAMP response element (CRE)-binding protein (CREB) and nuclear factor of activated T cells (NFAT), respectively1. The importance of the calcineurin-NFAT pathway in bone metabolism has been demonstrated in osteoclasts, osteoblasts and chondrocytes2,3,4,5. However, the contribution of the CaMK-CREB pathway is poorly understood, partly because of the difficulty of dissecting the functions of homologous family members6,7,8. Here we show that the CaMKIV-CREB pathway is crucial for osteoclast differentiation and function. Pharmacological inhibition of CaMKs as well as the genetic ablation of Camk4 reduced CREB phosphorylation and downregulated the expression of c-Fos, which is required for the induction of NFATc1 (the master transcription factor for osteoclastogenesis2,3) that is activated by receptor activator of NF-κB ligand (RANKL). Furthermore, CREB together with NFATc1 induced the expression of specific genes expressed by differentiated osteoclasts. Thus, the CaMK-CREB pathway biphasically functions to regulate the transcriptional program of osteoclastic bone resorption, by not only enhancing induction of NFATc1 but also facilitating NFATc1-dependent gene regulation once its expression is induced. This provides a molecular basis for a new therapeutic strategy for bone diseases.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Berridge, M.J., Lipp, P. & Bootman, M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1, 11–21 (2000).

  2. 2

    Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889–901 (2002).

  3. 3

    Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261–1269 (2005).

  4. 4

    Koga, T. et al. NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11, 880–885 (2005).

  5. 5

    Ranger, A.M. et al. The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J. Exp. Med. 191, 9–22 (2000).

  6. 6

    Long, F., Schipani, E., Asahara, H., Kronenberg, H. & Montminy, M. The CREB family of activators is required for endochondral bone development. Development 128, 541–550 (2001).

  7. 7

    Zayzafoon, M., Fulzele, K. & McDonald, J.M. Calmodulin and calmodulin-dependent kinase IIα regulate osteoblast differentiation by controlling c-fos expression. J. Biol. Chem. 280, 7049–7059 (2005).

  8. 8

    Seales, E.C., Micoli, K.J. & McDonald, J.M. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J. Cell. Biochem. 97, 45–55 (2006).

  9. 9

    Harada, S. & Rodan, G.A. Control of osteoblast function and regulation of bone mass. Nature 423, 349–355 (2003).

  10. 10

    Soderling, T.R. & Stull, J.T. Structure and regulation of calcium/calmodulin-dependent protein kinases. Chem. Rev. 101, 2341–2352 (2001).

  11. 11

    Silva, A.J., Stevens, C.F., Tonegawa, S. & Wang, Y. Deficient hippocampal long-term potentiation in α-calcium-calmodulin kinase II mutant mice. Science 257, 201–206 (1992).

  12. 12

    Bito, H., Deisseroth, K. & Tsien, R.W. CREB phosphorylation and dephosphorylation: a Ca2+- and stimulus duration-dependent switch for hippocampal gene expression. Cell 87, 1203–1214 (1996).

  13. 13

    Ho, N. et al. Impaired synaptic plasticity and cAMP response element-binding protein activation in Ca2+/calmodulin-dependent protein kinase type IV/Gr-deficient mice. J. Neurosci. 20, 6459–6472 (2000).

  14. 14

    Kang, H. et al. An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory. Cell 106, 771–783 (2001).

  15. 15

    Anderson, K.A. & Means, A.R. Defective signaling in a subpopulation of CD4+ T cells in the absence of Ca2+/calmodulin-dependent protein kinase IV. Mol. Cell. Biol. 22, 23–29 (2002).

  16. 16

    Kitsos, C.M. et al. Calmodulin-dependent protein kinase IV regulates hematopoietic stem cell maintenance. J. Biol. Chem. 280, 33101–33108 (2005).

  17. 17

    Sumi, M. et al. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 181, 968–975 (1991).

  18. 18

    Tokumitsu, H. et al. STO-609, a specific inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase. J. Biol. Chem. 277, 15813–15818 (2002).

  19. 19

    See, V., Boutillier, A.L., Bito, H. & Loeffler, J.P. Calcium/calmodulin-dependent protein kinase type IV (CaMKIV) inhibits apoptosis induced by potassium deprivation in cerebellar granule neurons. FASEB J. 15, 134–144 (2001).

  20. 20

    Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600–605 (2000).

  21. 21

    Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758–763 (2004).

  22. 22

    Shaywitz, A.J. & Greenberg, M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821–861 (1999).

  23. 23

    Ahn, S. et al. A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol. Cell. Biol. 18, 967–977 (1998).

  24. 24

    Takayanagi, H. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416, 744–749 (2002).

  25. 25

    Sheng, M. & Greenberg, M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4, 477–485 (1990).

  26. 26

    Garcia-Rodriguez, C. & Rao, A. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J. Exp. Med. 187, 2031–2036 (1998).

  27. 27

    Aoki, K. et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J. Clin. Invest. 116, 1525–1534 (2006).

  28. 28

    Herzig, S. et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183 (2001).

  29. 29

    Tokumitsu, H. et al. Mechanism of the generation of autonomous activity of Ca2+/calmodulin-dependent protein kinase IV. J. Biol. Chem. 279, 40296–40302 (2004).

  30. 30

    Kim, Y. et al. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J. Biol. Chem. 280, 32905–32913 (2005).

Download references

Acknowledgements

We are grateful to M.A. Brown (Northwestern University Feinberg School of Medicine), T. Kitamura (Institute of Medical Science, University of Tokyo), R.A. Maurer (Oregon Health & Science University,), T. Miyakawa (Graduate School of Medicine, Kyoto University), N. Nozaki (Kanagawa Dental College), G.D. Roodman (University of Pittsburgh), M. Montminy (Salk Institute for Biological Studies), V. See (Université Louis Pasteur), C. Vinson (National Cancer Institute), Seikagaku Corporation and the RNAi Co. Ltd. for providing materials. We also thank J. Taka, Y. Suzuki, H. Murayama, H. Saito, M. Asagiri, M. Shinohara, T. Koga, H.J. Gober, T. Kunigami, Y. Kim, U. Sato and I. Takayanagi for technical assistance and discussion. This work was supported in part by the Solution Oriented Research for Science and Technology (SORST) program of the Japan Science and Technology Agency (JST); a Grant-in-Aid for Creative Scientific Research from the Japan Society for the Promotion of Science (JSPS); grants for the Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); grants for the 21st Century Center of Excellence program from MEXT; Grants-in Aid for Scientific Research from MEXT; Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan; and grants from the Naito Foundation, Suzuken Memorial Foundation, Uehara Memorial Foundation, Kato Memorial Bioscience Foundation, Cell Science Research Foundation and the Nakatomi Foundation.

Author information

K.S. and A.S. contributed equally to the manuscript by conducting most of the in vivo and in vitro experiments and by cooperating in the preparation of the manuscript. T.N. supported the in vivo and in vitro experiments, conducted the data analyses and contributed to the manuscript preparation. S.T.-K. and H.B. prepared the plasmids and provided advice on project planning, data interpretation and manuscript preparation. K.A. and K.O. supported the in vivo experiments. Y.M. and A.Y. conducted the histopathological analyses. H.A. prepared the plasmids and contributed to the data analyses. T.T. and T.A.C. generated the genetically modified mice and contributed to the data analyses. T.K. conducted the GeneChip experiments and data analyses. H.T. designed and supervised the project, and wrote the manuscript.

Correspondence to Haruhiko Bito or Hiroshi Takayanagi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Further reading

Figure 1: Contribution of CaMKs in RANKL-induced osteoclastogenesis.
Figure 2: Impairment of osteoclast differentiation in Camk4−/− mice under physiological and pathological conditions.
Figure 3: CaMKIV-mediated CREB activation is required for the induction of c-Fos and NFATc1 by RANKL.
Figure 4: Regulation of osteoclast activity by the CaMK-CREB pathway and therapeutic implications.